巴基斯坦实现丙型肝炎消除的健康与经济收益:建模研究与经济分析
该建模研究评估巴基斯坦实现HCV消除(2030年发病率降80%)的健康与经济影响。
核心结论
- 投资HCV消除可为巴基斯坦带来显著健康与经济收益。
研究设计与样本
- 改编巴基斯坦HCV传播模型,估计消除策略(2030年发病率降80%)的影响、成本与成本效果。
- 策略包括独立服务提供或部分整合三分之一初始HCV检测至现有医疗服务。
- 比较筛查、治疗和管理投资与减少缺勤、假性出勤和过早死亡带来的生产力收益。
关键数值与推荐
- 消除定义:2030年HCV年发病率较基线降低80%。
- 支付意愿阈值:巴基斯坦机会成本阈值148-198美元/DALY。
- ICER=29美元/DALY(消除策略 vs 维持现有治疗水平)。
临床怎么用
- 可优先考虑将部分HCV检测整合至现有医疗服务以降低成本。
- 消除策略具有高成本效果,长期可产生净经济收益。
局限性
- 现有初级医疗服务可整合程度存在不确定性。
- 缺乏巴基斯坦特异性疾病相关管理成本和生产力损失数据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Modelling suggests that achieving the WHO incidence target for hepatitis C virus (HCV) elimination in Pakistan could cost US$3.87 billion over 2018 to 2030. However, the economic benefits from integrating services or improving productivity were not included. METHODS AND FINDINGS: We adapt a HCV transmission model for Pakistan to estimate the impact, costs, and cost-effectiveness of achieving HCV elimination (reducing annual HCV incidence by 80% by 2030) with stand-alone service delivery, or partially integrating one-third of initial HCV testing into existing healthcare services. We estimate the net economic benefits by comparing the required investment in screening, treatment, and healthcare management to the economic productivity gains from reduced HCV-attributable absenteeism, presenteeism, and premature deaths. We also calculate the incremental cost-effectiveness ratio (ICER) per disability-adjusted life year (DALY) averted for HCV elimination versus maintaining current levels of HCV treatment. This is compared to an opportunity cost-based willingness-to-pay threshold for Pakistan (US$148 to US$198/DALY). Compared to existing levels of treatment, scaling up screening and treatment to achieve HCV elimination in Pakistan averts 5.57 (95% uncertainty interval (UI) 3.80 to 8.22) million DALYs and 333,000 (219,000 to 509,000) HCV-related deaths over 2018 to 2030. If HCV testing is partially integrated, this scale-up requires an investment of US$1.45 (1.32 to 1.60) billion but will result in US$1.30 (0.94 to 1.72) billion in improved economic productivity over 2018 to 2030. This elimination strategy is highly cost-effective (ICER = US$29 per DALY averted) by 2030, with it becoming cost-saving by 2031 and having a net economic benefit of US$9.10 (95% UI 6.54 to 11.99) billion by 2050. Limitations include uncertainty around what level of integration is possible within existing primary healthcare services as well as a lack of Pakistan-specific data on disease-related healthcare management costs or productivity losses due to HCV. CONCLUSIONS: Investment in HCV elimination can bring about substantial societal health and economic benefits for Pakistan.
引用
- Lim AG, Scott N, Walker JG, et al. Health and economic benefits of achieving hepatitis C virus elimination in Pakistan: A modelling study and economic analysis. PLoS Med. 2021. PMID: 34665815. doi:10.1371/journal.pmed.1003818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。